 |
3 Products |  |
0 Diseases | | 3 Products |
|
18 Trials |  |
2079 News |  |
| «12...12131415161718192021222324 |
- Ocaliva (obeticholic acid) / Intercept
Trial primary completion date: OCABSGS: Obeticholic Acid in Bariatric and Gallstone Disease (clinicaltrials.gov) - May 12, 2014
P2, N=40, Recruiting, Sponsor: Sahlgrenska University Hospital, Sweden
Trial primary completion date: Jun 2013 --> Sep 2014
- Ocaliva (obeticholic acid) / Intercept
Trial initiation date: OCABSGS: Obeticholic Acid in Bariatric and Gallstone Disease (clinicaltrials.gov) - May 12, 2014
P2, N=40, Recruiting, Sponsor: Sahlgrenska University Hospital, Sweden
Trial primary completion date: Jun 2013 --> Sep 2014 Initiation date: Sep 2012 --> Sep 2013
- Ocaliva (obeticholic acid) / Intercept
Trial completion date: OCABSGS: Obeticholic Acid in Bariatric and Gallstone Disease (clinicaltrials.gov) - May 12, 2014
P2, N=40, Recruiting, Sponsor: Sahlgrenska University Hospital, Sweden
Initiation date: Sep 2012 --> Sep 2013 Trial completion date: Dec 2013 --> Mar 2015
- Ocaliva (obeticholic acid) / Intercept
Enrollment open: OCABSGS: Obeticholic Acid in Bariatric and Gallstone Disease (clinicaltrials.gov) - May 12, 2014
P2, N=40, Recruiting, Sponsor: Sahlgrenska University Hospital, Sweden
Trial completion date: Dec 2013 --> Mar 2015 Not yet recruiting --> Recruiting
- Ocaliva (obeticholic acid) / Intercept
Trial initiation date: Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) (clinicaltrials.gov) - Apr 9, 2014
P2, N=60, Not yet recruiting, Sponsor: Indiana University
Not yet recruiting --> Recruiting Initiation date: Mar 2014 --> Jun 2014
- | Ocaliva (obeticholic acid) / Intercept
New P2 trial: Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) (clinicaltrials.gov) - Jan 15, 2014
P2, N=60, Not yet recruiting, Sponsor: Indiana University
- | Ocaliva (obeticholic acid) / Intercept
Trial initiation date: Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis (clinicaltrials.gov) - Dec 11, 2013
P2, N=25, Recruiting, Sponsor: Intercept Pharmaceuticals
Initiation date: Mar 2014 --> Jun 2014 Initiation date: Aug 2013 --> Nov 2013
- | Ocaliva (obeticholic acid) / Intercept
Trial completion: Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA) (clinicaltrials.gov) - Dec 3, 2013
P1, N=24, Completed, Sponsor: Intercept Pharmaceuticals
Initiation date: Aug 2013 --> Nov 2013 Not yet recruiting --> Completed
- | Ocaliva (obeticholic acid) / Intercept
Enrollment open: Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis (clinicaltrials.gov) - Oct 22, 2013
P2, N=25, Recruiting, Sponsor: Intercept Pharmaceuticals
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- | Ocaliva (obeticholic acid) / Intercept
Trial completion: Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA) (clinicaltrials.gov) - Oct 22, 2013
P1, N=32, Completed, Sponsor: Intercept Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- | Ocaliva (obeticholic acid) / Intercept
Trial completion: Hepatic Impairment Trial of Obeticholic Acid (clinicaltrials.gov) - Oct 22, 2013
P1, N=32, Completed, Sponsor: Intercept Pharmaceuticals
Not yet recruiting --> Completed Recruiting --> Completed
- | Ocaliva (obeticholic acid) / Intercept
New P1 trial: Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA) (clinicaltrials.gov) - Aug 29, 2013
P1, N=24, Completed, Sponsor: Intercept Pharmaceuticals
- | Ocaliva (obeticholic acid) / Intercept
New P1 trial: Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA) (clinicaltrials.gov) - Jul 31, 2013
P1, N=32, Completed, Sponsor: Intercept Pharmaceuticals
- | Ocaliva (obeticholic acid) / Intercept
New P1 trial: Hepatic Impairment Trial of Obeticholic Acid (clinicaltrials.gov) - Jul 18, 2013
P1, N=32, Completed, Sponsor: Intercept Pharmaceuticals
- | Ocaliva (obeticholic acid) / Intercept
New P2 trial: Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis (clinicaltrials.gov) - May 29, 2013
P2, N=25, Recruiting, Sponsor: Intercept Pharmaceuticals
- ||||| Ocaliva (obeticholic acid) / Intercept
Enrollment closed: POISE: Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Dec 18, 2012
P3, N=180, Active, not recruiting, Sponsor: Intercept Pharmaceuticals
Recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- Ocaliva (obeticholic acid) / Intercept
Enrollment open: OBADIAH1: Obeticholic Acid in Bile Acid Diarrhoea (clinicaltrials.gov) - Nov 29, 2012
P2, N=30, Recruiting, Sponsor: Imperial College London
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- Ocaliva (obeticholic acid) / Intercept
Enrollment closed: The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT) (clinicaltrials.gov) - Nov 7, 2012
P2, N=283, Active, not recruiting, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Ocaliva (obeticholic acid) / Intercept
New P2 trial: OCABSGS: Obeticholic Acid in Bariatric and Gallstone Disease (clinicaltrials.gov) - Jun 19, 2012
P2, N=40, Not yet recruiting, Sponsor: Sahlgrenska University Hospital, Sweden
- Ocaliva (obeticholic acid) / Intercept
New P2 trial: OBADIAH1: Obeticholic Acid in Bile Acid Diarrhoea (clinicaltrials.gov) - Apr 23, 2012
P2, N=30, Recruiting, Sponsor: Imperial College London
- ||| Ocaliva (obeticholic acid) / Intercept
Enrollment change: Study of INT-747 in Patients With Diabetes and Presumed NAFLD (clinicaltrials.gov) - Apr 16, 2012
P2, N=64, Completed, Sponsor: Intercept Pharmaceuticals
Recruiting --> Active, not recruiting N=45 --> 64
- |||||||||| Ocaliva (obeticholic acid) / Intercept
New P3 trial: POISE: Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Nov 15, 2011
P3, N=180, Active, not recruiting, Sponsor: Intercept Pharmaceuticals